<table id="ID155" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 16. Mean Pharmacokinetic Parameters in Pediatric Patients With Epilepsy </caption>
<col span="1" width="35%"></col>
<col span="1" width="20%"></col>
<col span="1" width="11%"></col>
<col span="1" width="17%"></col>
<col span="1" width="17%"></col>
<tbody>
<tr>
<td>Pediatric Study Population<br/>
</td>
<td>Number of Subjects<br/>
</td>
<td>T<sub>m</sub>
<sub>a</sub>
<sub>x</sub>(hr)<br/>
</td>
<td>t<sub>1</sub>
<sub>/</sub>
<sub>2</sub>
<sub> </sub>hr)<br/>
</td>
<td>Cl/F<br/>(mL/min/kg)<br/>
</td>
</tr>
<tr>
<td>
<content stylecode="bold">Ages </content>
<content stylecode="bold">10 </content>
<content stylecode="bold">months</content>
<content stylecode="bold">-</content>
<content stylecode="bold">5</content>
<content stylecode="bold">.</content>
<content stylecode="bold">3 </content>
<content stylecode="bold">years</content>
<content stylecode="bold">
<br/>
</content>Patients taking carbamazepine,<br/>phenytoin, phenobarbital, or<br/>primidone<sup>a</sup>
<br/>Patients taking AEDs with no known effect on the apparent clearance of lamotrigine<br/>
<br/>Patients taking valproate only<br/>
</td>
<td>
<br/>10<br/>
<br/>
<br/>7<br/>
<br/>
<br/>8<br/>
</td>
<td>
<br/>3.0<br/>(1.0-5.9)<br/>
<br/>5.2<br/>(2.9-6.1)<br/>
<br/>2.9<br/>(1.0-6.0)<br/>
</td>
<td>
<br/>7.7 <br/>(5.7-11.4)<br/>
<br/>19.0 <br/>(12.9-27.1)<br/>
<br/>44.9 <br/>(29.5<content stylecode="italics">-</content>52.5)<br/>
</td>
<td>
<br/>3.62 <br/>(2.44-5.28)<br/>
<br/>1.2 <br/>(0.75-2.42)<br/>
<br/>0.47 <br/>(0.23-0.77)<br/>
</td>
</tr>
<tr>
<td>
<content stylecode="bold">Ages </content>
<content stylecode="bold">5</content>
<content stylecode="bold">-</content>
<content stylecode="bold">11 </content>
<content stylecode="bold">years </content>
<content stylecode="bold">
<br/>
</content>
<content stylecode="bold">  </content>Patients taking carbamazepine, <br/>  phenytoin, phenobarbital, or   <br/>  primidone<sup>a</sup>  Patients taking carbamazepine, <br/> phenytoin, phenobarbital, or<br/> primidone<sup>a</sup> plus valproate <br/>Patients taking valproate only<sup>b</sup>
<br/>
</td>
<td>
<br/>7<br/>
<br/>
<br/>8<br/>
<br/>3<br/>
</td>
<td>
<br/>1.6 <br/>(1.0-3.0)<br/>
<br/>3.3 <br/>(1.0-6.4)<br/>
<br/>4.5 <br/>(3.0-6.0)<br/>
</td>
<td>
<br/>7.0 <br/>(3.8-9.8) <br/>
<br/>19.1 <br/>(7.0-31.2)<br/>
<br/>65.8 <br/>(50.7-73.7)<br/>
</td>
<td>
<br/>2.54 <br/>(1.35-5.58)<br/>
<br/>0.89 <br/>(0.39-1.93)<br/>
<br/> 0.24 <br/>(0.21-0.26)<br/>
</td>
</tr>
<tr>
<td>
<content stylecode="bold">Ages </content>
<content stylecode="bold">13</content>
<content stylecode="bold">-</content>
<content stylecode="bold">18 </content>
<content stylecode="bold">years </content>
<content stylecode="bold">
<br/>
</content>  Patients taking carbamazepine, phenytoin, phenobarbital, or primidone<sup>a</sup> <br/>  Patients taking carbamazepine,<br/>  phenytoin, phenobarbital, <br/>or primidone<sup>a</sup> plus valproate <br/>  Patients taking valproate only  <br/>
</td>
<td>
<br/>11<br/>
<br/>
<br/>8<br/>
<br/>4<br/>
</td>
<td>
<br/>c<br/>
<br/>
<br/>c<br/>
<br/>c<br/>
</td>
<td>
<br/>c<br/>
<br/>
<br/>c<br/>
<br/>c<br/>
</td>
<td>
<br/>1.3<br/>
<br/>
<br/>0.5<br/>
<br/>0.3<br/>
</td>
</tr>
<tr>
<td>
<paragraph></paragraph>
<paragraph>
<sup>a</sup> Carbamazepine, phenobarbital, phenytoin, and primidone have been shown to increase the apparent clearance of lamotrigine. Estrogen-containing oral contraceptives and rifampin have also been shown to increase the apparent clearance of lamotrigine <content stylecode="italics">[see Drug Interactions <linkhtml href="#ID112">(7)</linkhtml>].</content>
</paragraph>
<paragraph>
<sup>b</sup> Two subjects were included in the calculation for mean T<sub>m</sub>
<sub>a</sub>
<sub>x</sub>
<sub>.</sub>
<br/>
</paragraph>
<paragraph>
<sup>c</sup> Parameter not estimated.<br/>
</paragraph>
</td>
</tr>
</tbody>
</table>